Rid­ing the wave on lat­est obe­si­ty buy­out; Slack in­ter­view with an­ti-ag­ing re­searcher; Two new IRA law­suits; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As sum­mer comes to an end, we are get­ting ready to launch a fresh back-to-school look for the End­points Week­ly. Thanks as al­ways for your read­er­ship, and stay tuned!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER